Study of Multiple Ascending Dose of KBL693 in Healthy Participants

NCT04307173 | Completed Phase 1 DMC

• 1 other identifier: KBL-CURE-2020-01
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

The study is designed to investigate the safety and tolerability of KBL693 in healthy volunteers. KBL693 has been developed as a potential new treatment for moderate to severe asthma..

Conditions

Moderate to Severe Asthma

Outcome Measures

Primary Outcomes (9)

• Safety and tolerability measure through Adverse Events/Serious Adverse Events

  Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

  Measurements at Baseline till 28 days

• Safety and tolerability(Incidence of Treatment-Emergent Adverse Events) measure through Vital Sign- blood pressure

  Measured by result of the Vital Sign- blood pressure

  Measurement at Baseline till 28 days

• Safety and tolerability(Incidence of Treatment-Emergent Adverse Events) measure through Vital Sign-heart rate

  Measured by result of the Vital Sign- heart rate

  Measurement at Baseline till 28 days

• Safety and tolerability(Incidence of Treatment-Emergent Adverse Events) measure through Vital Sign- axillary body temperature

  Measured by result of the Vital Sign- axillary body temperature

  Measurement at Baseline till 28 days

• Safety and tolerability(Incidence of Treatment-Emergent Adverse Events) measure through Vital Sign- respiratory rate

  Measured by result of the Vital Sign- respiratory rate

  Measurement at Baseline till 28 days

• Safety and tolerability(Incidence of Treatment-Emergent Adverse Events) measure through 12-lead ECG

  Measured by result of the ECG measurements and findings

  Measurement at Baseline till 28 days

• Safety and tolerability(Incidence of Treatment-Emergent Adverse Events) measure through Physical exam

  Measured by result of the physical exam which includes general appearance, skin, eyes/ears/nose/throat, head and neck, cardiovascular, respiratory, abdomen, extremities, lymph nodes, musculoskeletal and neurologic

  Measurement at Baseline till 28 days

• Safety and tolerability(Incidence of Treatment-Emergent Adverse Events) measure through Routine Stool Examination

  Measured by result of the Bristol Stool Examination, Occult blood, Parasites

  Measurement at Baseline till 28 days

• Safety and tolerability(Incidence of Treatment-Emergent Adverse Events) measure through Clinical laboratory results

  Measured by clinically significant change from baseline clinical laboratory results

  Measurement at Baseline till 28 days

Secondary Outcomes (1)

• Difference in the change from baseline in profile of faecal KBL693 between treatment arms

  Measurements at Baseline till 28 days

Study Arms (2)

Cohort 1

EXPERIMENTAL

9 subjects for MAD 1 cohort. 6 subjects on KBL693, 3 subjects on placebo.

Drug: KBL693

Cohort 2

EXPERIMENTAL

9 subjects for MAD 2 cohort. 6 subjects on KBL693, 3 subjects on placebo.

Drug: KBL693

Interventions

KBL693 DRUG

Part 1: 680 mg/day of KBL693 or Placebo; Route of Administration: Oral

Also known as: Placebo

Cohort 1

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy volunteers (also referred to as participants) who can read and understand, and are willing to sign the informed consent form
• Willing and able to comply with clinic visits (including confinement to CTU) and study-related procedures
• Male or female healthy volunteers aged ≥18 and ≤65 years at Screening
• Body mass index (BMI) of ≥18.0 kg/m2 to ≤32 kg/m2 (both inclusive) at Screening
• Normal hemodynamic parameters: systolic blood pressure (BP) ≥90 mmHg and ≤140 mmHg; diastolic BP ≥50 mmHg and ≤90 mmHg; heart rate (HR) ≥40 bpm and ≤100 bpm at Screening and Day -1. Measurements may be repeated up to 3 times at the discretion of the investigator.
• Please note: participants with out of range values, which are not clinically significant as per the principal investigator's (PI) discretion, will be allowed. The PI may delegate this responsibility to a suitably qualified and trained study team member.
• The participant is, in the opinion of the PI (or delegate), generally healthy based on assessment of medical history, physical examination, vital signs, ECG, and the results of the haematology, clinical chemistry, urinalysis, serology, and other relevant laboratory tests
• Baseline laboratory test values within reference ranges based on the blood and urine samples taken at Screening and on Day -1. Out of normal ranges values may be accepted by the PI, if not clinically significant
• Have regular bowel movements (e.g., once daily)
• Male participants must agree to practise true abstinence; be surgically sterilised (performed at least 6 months prior); or agree to use of a condom if sexually active with a female partner of childbearing potential, from Screening through 90 days after the final dose of the investigational product (IP).
• Women of child-bearing potential must agree to practise true abstinence or agree to use effective contraception from Screening through 90 days after the final dose of the IP.
• Effective contraception includes:
• Oral contraceptives ("the pill") for at least 1 month prior to Day 1, plus use of a condom
• Depot or injectable birth control or implantable contraception (e.g., Implanon) plus use of a condom
• Intrauterine device plus use of a condom

You may not qualify if:

• Female participants who are pregnant or lactating
• The participant's corrected QT interval (QTcF) (Fridericia's correction) is \>450 msec (males), and \>470 msec (females) at Screening or on Day -1. An out-of-range or abnormal ECG will be repeated at PI's discretion. In total, 3 ECGs should be recorded consecutively at Screening and on Day -1, and the PI (or delegate) must evaluate the triplicate ECG. If the participant's QTcF is \>450 msec (males) or \>470 msec (females) on at least 2 ECGs or have structural cardiac abnormalities, the participant must be excluded
• The participant has taken prescription (including antibiotics) or non-prescription medication, herbal remedies, vitamins or minerals, any probiotic drinks and yeast supplements (e.g. Mutaflor®, Bioflor®) within 14 days prior to the first dose of study product unless in the opinion of the PI the medication will not compromise participant safety or interfere with study procedures or data validity. Participant may be rescreened after a washout period of 14 days. Please note use of oral contraceptives and paracetamol up to 2 g/day and/or nonsteroidal anti-inflammatory drugs for symptomatic relief of minor symptoms are allowed
• Participant has functional GI disorders
• Participant is a current smoker or has used nicotine containing products within 6 months prior to Screening visit
• The participant has a substance abuse-related disorder or has a history of drug, alcohol and/or substance abuse deemed significant by the PI
• The participant has taken any IP within 30 days prior to the first dose of study product or 5 half-lives, whichever is longer
• The participant has a history of significant hypersensitivity or anaphylaxis involving any drug (including ampicillin, clindamycin or imipenem), any constituent of the IP, food or other precipitating agent (e.g. bee sting). Please note participants with clinically stable mild allergic conditions such as hay fever and mild eczema may be enrolled at the discretion of the PI
• Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus antibody (anti-HCV)at Screening visit.
• Positive screen for drugs of abuse and cotinine at Screening or on Day -1. Positive screen for alcohol on Day -1.
• The participant is, in the opinion of the PI, unlikely to comply with the clinical study protocol or is unsuitable for any other reason.

Sponsors & Collaborators

• KoBioLabs: lead
• Novotech (Australia) Pty Limited: collaborator

Study Sites (1)

Linear Clinical Research

Nedlands, Western Australia, 6009, Australia

Location

Study Officials

• Lara Hatchuel, Dr

  Linear Clinical Research

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 21, 2020
• First Posted: March 13, 2020
• Study Start: August 14, 2020
• Primary Completion: October 30, 2020
• Study Completion: November 12, 2020
• Last Updated: February 21, 2021

Record last verified: 2021-02

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)